Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
02 September 2020 | Story Lacea Loader | Photo Charl Devenish
Deputy Minister visit
From the left are: Deputy Minister of Higher Education, Science and Technology, Buti Manamela; Prof Prakash Naidoo, Vice-Rector: Operations at the UFS; and Dr Ramneek Ahluwalia, Chief Executive Officer of Higher Health.

“The work that the University of the Free State (UFS) is doing to ensure that students get the necessary support is quite impressive. The university is saving the academic year to save lives.” These were the words of the Deputy Minister of Higher Education, Science and Technology, Buti Manamela, during a visit to the university’s Bloemfontein Campus on 31 August 2020.

The visit was part of the Deputy Minister’s visit to higher education institutions in Bloemfontein to assess the academic state of readiness and to monitor the safety protocols for the phased re-opening of campuses during Level 2 of the national lockdown.

The delegation, which also consisted of representatives from Higher Health led by the Chief Executive Officer Dr Ramneek Ahluwalia, attended a briefing session in the Council Chambers before visiting various venues on campus. In his opening and welcoming remarks, Prof Prakash Naidoo, Vice-Rector: Operations, said that the safety, health, and well-being of staff and students remain the university’s priority. “Extensive planning has gone into making sure that the university complies with the national COVID-19 protocols and regulations and that our campuses are safe and ready for the return of students. Sufficient hygiene measures are in place, as well as adaptions to ensure physical distancing. The wearing of masks, physical distancing, and hand sanitising remain compulsory on all the campuses,” said Prof Naidoo.

“A Special Executive Group (SEG) was already established by the Rector and Vice-Chancellor, Prof Francis Petersen, at the beginning of March 2020. The SEG meets weekly to discuss and decide on the university’s response to COVID-19 as this pandemic develops over time. Consisting of eight task teams, the SEG is the decision-making entity that responds rapidly and in a coordinated manner to combat the threats to business continuity. One of the task teams is specifically looking at the wellness of our students and staff to make sure that this important aspect is taken care of,” said Prof Naidoo.

During a presentation of the university’s Multimodal Teaching and Learning Plan for the completion of the 2020 academic year, Prof Francois Strydom, Senior Director: Centre for Teaching and Learning, said that the university has an evidence-based approach towards remote multimodal teaching, learning, and assessment. “For instance, our vulnerable students were identified early in the lockdown, and 16 strategies were put in place to ensure that no student is left behind. 99,95% of our students were active on Blackboard. We are developing plans for the 0,05% of students who were not able to participate in learning, so that they can continue their learning journey with the UFS,” said Prof Strydom.

In his closing remarks, Deputy Minister Manamela commended the university management on the initiatives to save the academic year. He also indicated his appreciation for the informative session and encouraged the university to keep on motivating students and staff to be attentive to their behaviour and to remain careful about their health and well-being.

The programme was concluded with a visit to a number of venues on campus, including the examination venues, the Health and Wellness Clinic, the Pathogen Research Laboratory of the Division of Virology and a student housing unit.

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept